Ipsen SA (IPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1638
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ipsen SA (IPN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in few countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Apr 22,2020 Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Apr 01,2020 Ipsen donates two million euros to the Institut Pasteur to support research on COVID-19
Feb 13,2020 Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Jan 14,2020 Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ipsen SA – Key Facts
Ipsen SA – Key Employees
Ipsen SA – Key Employee Biographies
Ipsen SA – Major Products and Services
Ipsen SA – History
Ipsen SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Specialty Care
Overview
Performance
Geographical Segment: Major Western European Countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA – Corporate Strategy
Ipsen SA – SWOT Analysis
SWOT Analysis – Overview
Ipsen SA – Strengths
Ipsen SA – Weaknesses
Ipsen SA – Opportunities
Ipsen SA – Threats
Ipsen SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 22, 2020: Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Apr 01, 2020: Ipsen donates two million euros to the Institut Pasteur to support research on COVID-19
Feb 13, 2020: Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Jan 14, 2020: Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Dec 18, 2019: Ipsen announces departure of David Meek as chief executive officer
Nov 05, 2019: Ipsen appoints Howard Mayer, M.D. as Executive Vice President and head of Research and Development
Oct 23, 2019: Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance
Oct 16, 2019: Ipsen gains licence to Blueprint Medicines’ FOP drug candidate
Jul 25, 2019: Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019
May 14, 2019: Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ipsen SA, Performance Chart (2015 - 2019)
Ipsen SA, Ratio Charts
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Ipsen SA (IPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Concord Medical Services Holdings Ltd (CCM):製薬・医療:M&Aディール及び事業提携情報
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • TE Connectivity Ltd.:企業の戦略・SWOT・財務情報
    TE Connectivity Ltd. - Strategy, SWOT and Corporate Finance Report Summary TE Connectivity Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • TPG Telecom Ltd (TPM):企業の財務・戦略的SWOT分析
    TPG Telecom Ltd (TPM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Fauji Fertilizer Bin Qasim Ltd (FFBL):企業の財務・戦略的SWOT分析
    Fauji Fertilizer Bin Qasim Ltd (FFBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • PolyPid Ltd (POLY):医療機器:M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Uptake Medical Corp-医療機器分野:企業M&A・提携分析
    Summary Uptake Medical Corp (Uptake Med) is a healthcare technology company that develops medical technologies for the treatment of emphysema and lung cancer. The company develops intervapor therapy system, a bronchoscopic procedure in which heated water vapor is delivered to emphysematous lung tiss …
  • Sberbank of Russia:企業のM&A・事業提携・投資動向
    Sberbank of Russia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sberbank of Russia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Bharat Heavy Electricals Ltd:企業の戦略・SWOT・財務分析
    Bharat Heavy Electricals Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharat Heavy Electricals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Epic Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Epic Sciences Inc (Epic Sciences) focuses to develop novel diagnostics for personalized treatment of cancer. The company develops AR-V7 test to identify and molecularly characterize circulating tumor cells in a blood sample. It also offers biopharma solutions such as resistance to AR signali …
  • Axela Inc:製品パイプライン分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Polskie Sieci Elektroenergetyczne SA:企業の戦略的SWOT分析
    Polskie Sieci Elektroenergetyczne SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Kerecis ehf:製薬・医療:M&Aディール及び事業提携情報
    Summary Kerecis ehf (Kerecis) is a medical device company that provides products that treats chronic wounds and damaged tissue. The company’s flagship product includes Kerecis Omega3 fish-skin acellular dermal matrix transplantation technology is intended for use in products to treat acute, chronic …
  • CardioNet Inc:医療機器:M&Aディール及び事業提携情報
    Summary CardioNet Inc (CardioNet), a subsidiary of BioTelemetry Inc is a medical device company that develops and markets medical telemetry devices for the healthcare sectors. The company provides proprietary technology and system, mobile cardiac outpatient telemetry that is used in the ECG monitori …
  • Wake Forest Innovations-製薬・医療分野:企業M&A・提携分析
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is an enterprise that advances the development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest University. The compa …
  • EDF Renewable Energy Inc:電力:M&Aディール及び事業提携情報
    Summary EDF Renewable Energy, Inc. (EDF Renewable Energy), formerly, enXco, Inc., is an integrated energy company. It designs, develops, constructs and operates renewable energy projects in the biogas, biomass, hydro, solar, wind and marine energy sectors; and provides storage solutions. It develops …
  • Solstad Farstad ASA (SOFF):石油・ガス:M&Aディール及び事業提携情報
    Summary Solstad Farstad ASA (Solstad), formerly Solstad Offshore ASA is an oil and gas company that provides vessel operation solutions. The company offers carbon footprint, climate neutral network, offshore shipping, green operations, and rainforest protection, documentation programs, and others. I …
  • Marriott International Inc:企業の戦略・SWOT・財務情報
    Marriott International Inc - Strategy, SWOT and Corporate Finance Report Summary Marriott International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Praxair Inc (PX)-エネルギー分野:企業M&A・提携分析
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company offers atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and builds …
  • Merck & Co Inc (MRK):医療機器:M&Aディール及び事業提携情報
    Summary Merck & Co Inc (Merck) is a biopharmaceutical company that focuses on the discovery, development, manufacture and commercialization of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for treating cardiovascular, cancer, immune …
  • Banco Popular Dominicano S.A.:企業の戦略・SWOT・財務情報
    Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆